These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 34395160)

  • 1. Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
    Elekofehinti OO; Iwaloye O; Molehin OR; Famusiwa CD
    In Silico Pharmacol; 2021; 9(1):49. PubMed ID: 34395160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
    Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
    J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of New Hydroxyethylamine Analogs against 3CL
    Kumar S; Sharma PP; Shankar U; Kumar D; Joshi SK; Pena L; Durvasula R; Kumar A; Kempaiah P; Poonam ; Rathi B
    J Chem Inf Model; 2020 Dec; 60(12):5754-5770. PubMed ID: 32551639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
    Bepari AK; Reza HM
    PeerJ; 2021; 9():e11261. PubMed ID: 33954055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
    Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
    Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
    J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2.
    Elekofehinti OO; Iwaloye O; Josiah SS; Lawal AO; Akinjiyan MO; Ariyo EO
    Mol Divers; 2021 Aug; 25(3):1761-1773. PubMed ID: 33201386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach.
    Fadaka AO; Aruleba RT; Sibuyi NRS; Klein A; Madiehe AM; Meyer M
    J Biomol Struct Dyn; 2022 May; 40(8):3416-3427. PubMed ID: 33200673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.
    Muhammad I; Rahman N; Gul-E-Nayab ; Niaz S; Basharat Z; Rastrelli L; Jayanthi S; Efferth T; Khan H
    Comput Biol Med; 2021 Jun; 133():104362. PubMed ID: 33894500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of SARS-CoV-2 3CL
    Tahir Ul Qamar M; Alqahtani SM; Alamri MA; Chen LL
    J Pharm Anal; 2020 Aug; 10(4):313-319. PubMed ID: 32296570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL
    Jha RK; Khan RJ; Parthiban A; Singh E; Jain M; Amera GM; Singh RP; Ramachandran P; Ramachandran R; Sachithanandam V; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022; 40(24):13392-13411. PubMed ID: 34644249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QSAR, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective benzotriazole-based SARS-CoV 3CL protease inhibitors.
    D'Souza S; Balaji S; K V P
    J Biomol Struct Dyn; 2022; 40(24):14247-14261. PubMed ID: 34877897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
    Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
    Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
    Majumder R; Mandal M
    J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
    Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of phytochemical compounds of
    Krupanidhi S; Abraham Peele K; Venkateswarulu TC; Ayyagari VS; Nazneen Bobby M; John Babu D; Venkata Narayana A; Aishwarya G
    J Biomol Struct Dyn; 2021 Sep; 39(15):5799-5803. PubMed ID: 32627715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL
    Rao P; Shukla A; Parmar P; Rawal RM; Patel BV; Saraf M; Goswami D
    J Biomol Struct Dyn; 2022 Jan; 40(1):348-360. PubMed ID: 32875950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.